








S30How to Treat MDS without Stem Cell Transplantation
Norbert GattermannAlthough allogeneic hematopoietic cell transplantation (HCT) is the only proven curative treatment for mye-
lodysplastic syndromes (MDS), it is only used to treat a minority of MDS patients. Themajority of patients are
too old or suffer from comorbidities rendering allogeneic HCT too risky. Alternative treatment strategies for
patients with higher risk MDS try to alter the natural course of disease by preventing or delaying leukemic
transformation. In patients with lower risk MDS, treatment is mainly focused onmaintaining or improving the
quality of life.
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For elderly patients with comorbidities, or those
electing not to recieve aggressive therapy, supportive
care is the mainstay of treatment. Supportive care in-
cludes red blood cell (RBC) or platelet transfusions,
hematopoietic growth factors, and antimicrobial
agents. Although chronic transfusion therapy is rou-
tine, it is not entirely without problems. RBC transfu-
sions may cause transfusion reactions and lead to
transfusion-related iron overload. The latter calls for
iron chelation therapy, which is another component
of supportive care. Platelet transfusions can cause
HLA sensitization, leading to a lack of platelet incre-
ments with subsequent transfusions. Patients with
myelodysplastic syndromes (MDS) often present
with neutropenia, and may also have granulocyte
dysfunction. Accordingly, antibiotic treatment is
frequently given. Granulocyte transfusions, which are
laborious and provide only short-term benefit, are
not widely used, nor recommended.
About 80% of MDS patients have a hemoglobin of
\10 g/dL at diagnosis [1], and the majority of these
become transfusion dependent. Anemia impairs the
quality of life, and has a detrimental effect on cardiac
function [2], which in turn, contributes to fatigue and
an increased risk of heart failure. There is a direct rela-
tionship between hemoglobin increases and improved
quality of life in patients with anemia. In MDS, it isr Ha¨matologie, Onkologie u. klinische Immunology
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tween 8 and 10 g/dL. However, it is not possible to
define a universally applicable hemoglobin threshold
for triggering transfusion. Transfusion therapy must
be adapted to the patient’s age, level of activity, comor-
bidities, and preference. Very likely a proportion of
MDS patients does not receive adequate support in
terms of RBC transfusions. This may reflect the at-
tempt to use available resources sparingly, but it has
not been systematically studied whether maintaining
a higher level of hemoglobin actually requires a more
intensive transfusion regimen.HEMATOPOIETIC GROWTH FACTORS
Erythropoietic Growth Factors
To circumvent the need for blood transfusions,
hematopoietic growth factors can be administered.
There is no evidence that MDS is caused by growth
factor deficiency, but treatment with erythropoietin
leads to increased hemoglobin levels or decreased
transfusion requirements in about 30% of patients.
High dosages are needed, and various dosing regimens
have been proposed. Recombinant human erythropoi-
etin (Epo) is given as subcutaneous injection 1 to 3
times per week, in a weekly dose of 30,000 to 80,000
units. Epo treatment is most promising if the endoge-
nous Epo levels are \200 U/L. Darbepoetin-alpha,
a long-acting form of Epo, is administered subcutane-
ously with intervals of 7 to 21 days, at doses of 150 to
300 mg per week. The response rates with Epo and
darbepoietin were almost identical (58% and 59%,
respectively) in a recent meta-analysis using unified
response criteria according to the international
working group (IWG) [3].
Several studies suggested that Epo achieves
stronger erythroid responses when combined with
Biol Blood Marrow Transplant 16:S30-S36, 2010 S31How to Treat MDS without Stem Cell Transplantationgranulocyte-colony stimulating factor (G-CSF) or
granulocyte macrophage-colony stimulating factor
(GM-CSF). However, a recent meta-analysis found
that response rates were comparable for the 2 Epo-
based therapeutic strategies [4]. Furthermore, Epo
monotherapy at higher doses of 60,000 to 80,000 U
weekly produced significantly higher response rates
(64.5%) than did standard oncology doses of 30,000
to 40,000 U weekly, either as a single agent (49%) or
in combination with G-CSF/GM-CSF (50.6%). In
addition, when transfusion-dependent patients were
assessed separately, both Epo monotherapy and its
combination with G-CSF/GM-CSF produced com-
parable and appreciable levels of transfusion indepen-
dence (28.8% and 24.8%, respectively). Nevertheless,
the combination with granulocyte-colony stimulating
factor (G-CSF) appears to be particularly beneficial
in patients with refractory anemia with ring sidero-
blasts (RARS) [5,6], where the 2 growth factors have
a synergistic antiapoptotic effect on erythroid
precursor cells [7].
The Scandinavian MDS Group has validated
a decision model for treating MDS patients with Epo
plus G-CSF [8]. A simple scoring system predicts
a good response if the endogenous serum Epo level
is relatively low and the patient needs less than 2 units
of red cells per month. Unfortunately, patients who are
in particular need of improvement usually do not fulfill
these criteria. For patients with a good or intermediate
score, responses to Epo plus G-CSF have median
durations of almost 2 years. Epo plus G-CSF does
not increase the risk of leukemic transformation and
is associated with improved survival [9].G-CSF
The use of G-CSF for infectious complications is
not supported by randomized clinical trials. Neverthe-
less, guidelines recommend the temporary use of
G-CSF for patients with neutropenia and recurrent
severe infections. Prophylaxis with G-CSF is not
endorsed, partly because it may increase the risk of
bleeding through deterioration of thrombocytopenia.Thrombopoietin-Like Factors
Stimulation of platelet production would be a wel-
come modality for patients with thrombocytopenia
and hemorrhagic diathesis. Unfortunately, recombi-
nant thrombopoietin (TPO) was shown to be immu-
nogenic, being neutralized by developing antibodies.
Interleukin (IL)-11 has been approved for treating
thrombocytopenia postchemotherapy. A phase II trial
in patients with MDS was disappointing (major plate-
let responses in 15%, and minor responses in 13% of
patients).However, boosting platelet production is now ex-
periencing a renaissance. In patients with idiopathic
thrombocytopenic purpura, where increased platelet
removal by splenic macrophages is accompanied by
impaired platelet production in the bone marrow
(BM), new thrombopoietin receptor agonists can
achieve substantial augmentation of healthy megakar-
yocyte maturation and platelet production. Currently,
2 platelet receptor agonists are available.
Romiplostim (Nplate) is a peptibody consisting
of an IgG-Fc fragment plus 2 peptide chains with 4
TPO receptor binding sites, which show no sequence
homology with endogenous TPO and are not immu-
nogenic. Romiplostim is given subcutaneously.
Elthrombopag (Promacta), the second TPO re-
ceptor agonist, is administered orally. Clinical trials
in patients with MDS are ongoing. Romiplostim has
been shown to ameliorate thrombocytopenia induced
by treatment with azacytidine or lenalidomide.
Immunosuppressive Treatment
The rationale for immunosuppressive treatment in
MDS is based on findings suggesting that an autoim-
mune attack against hematopoietic precursor cells
contributes to hematopoietic failure. Treatment with
antithymocyte globulin (ATG), given alone or in com-
bination with cyclosporine (CsA) or other agents, im-
proves cell counts in approximately a third of patients;
responses may be delayed by several months. As yet,
there is no clear evidence of a survival advantage with
this treatment. BM hypoplasia, shorter duration of
transfusion dependence, and the presence of HLA-
DR15 may be associated with a higher probability of
response. Other immunosuppressive agents, for exam-
ple, alemtuzumab, are currently being investigated.
Lenalidomide
Thalidomide, by incompletely understood mecha-
nisms of action, produced response rates of 20% to
35% in patients with MDS, more so in low-risk than
in high-risk disease, and primarily in the erythroid lin-
eage. Interestingly, some patients experienced cytoge-
netic remissions [10]. Responses are generally of short
duration and because of significant side effects, mainly
fatigue and peripheral neuropathy, thalidomide tends
to be tolerated only for limited periods of time.
A chemical modification of thalidomide resulted in
lenalidomide, which is better tolerated primarily
because its basically lacking neurological toxicity.
Lenalidomide was approved by the U.S. Food and
Drug Administration (FDA) in December 2005, for
treatment of MDS with del(5q) cytogenetic abnormal-
ities. Two-thirds of such patients became transfusion-
independent in a large trial. The median time to
response was about 1 month. Responses were
impressive, with a median increase in hemoglobin of
S32 Biol Blood Marrow Transplant 16:S30-S36, 2010Norbert Gattermann5.4 g/dL. The median response duration was around 2
years. Patients reaching complete remissions (CRs)
may benefit even longer. The frequency of cytogenetic
response was not significantly different between pa-
tients with an isolated 5q deletion, patients who had
1 additional abnormality, and patients with a complex
karyotype. However, treatment is less effective in pa-
tients with increased BM blasts.
Lenalidomide was also tested in lower risk MDS
patients without del 5q [11]. Achieving transfusion in-
dependence was unrelated to karyotype, but occurred
in only 27% of patients. Erythroid improvement was
achieved in 43%, and the median duration of transfu-
sion independence was 10 months.
Neutropenia and thrombocytopenia are the most
common adverse events, occurring less frequently in
’’non-5q‘‘ than in del(5q) patients where lenalidomide
is more potent. The cytopenias are usually manageable
with dose reduction or interruption of therapy.
Although lenalidomide appears to be a major step
forward in the management of lower risk MDS, the
drug is not yet approved by the European Medicines
Agency (EMEA), because of concern about leukemic
transformations that were observed in a German cen-
ter on extended follow-up after a clinical trial. How-
ever, data from the large Du¨sseldorf MDS Registry
show that the rate of spontaneous acute myelogenous
leukemia (AML) development in patients with del5q
(not treated with lenalidomide) is practically the
same as in patients treated with lenalidomide. A new
randomized trial has recently been started in Germany
that will address this issue.
Low-Dose Chemotherapy
Low-dose chemotherapy with cytosine arabino-
side has minimal organ toxicity, but can cause signifi-
cant BM suppression. There are reports of CRs, but
there is no evidence of significantly improved survival
with this treatment. Low-dose AraC was clearly infe-
rior to 5-azacitidine in the randomized prospective
AZA-001 trial (see the following section).
Low-dose melphalan (Mel) is also well tolerated,
but useful mainly in patients with hypoplastic MDS
[12]. In our experience, temporary improvement in
blood cell counts comes at the price of a high rate of
leukemic transformation.
Intensive Chemotherapy
Intensive chemotherapy yields lower remission
rates in MDS than in AML, and long-term remission
is achieved in\20% of patients. Intensive chemother-
apy is an option for patients with a high risk of leuke-
mic transformation. It requires the absence of severe
comorbidities and the absence of complex cytogenetic
abnormalities. A complex karyotype is associated with
a poor chance to achieve CR and a high risk of earlyrelapse. In our view, intensive chemotherapy is not in-
dicated for elderly patients with high-risk MDS or
AML if a complex karyotype is present [13]. In youn-
ger patients with a more favorable karyotype, high-
dose chemotherapy may induce CRs and thereby
open the door to allogeneic hematopoietic cell trans-
plantation (HCT).Epigenetic Treatment
If chemotherapy is not an option, epigenetic treat-
ment offers another chance, particularly for patients
with higher risk MDS. Epigenetic changes refer to
heritable, but potentially reversible, modifications of
DNA and chromatin that regulate gene transcription
but are not caused by irreversible changes such as mu-
tations or deletions. Epigenetic control of gene expres-
sion involves DNA methylation, particularly in the
promotor region of genes, as well as a combination
of different modifications, for example, acetylation,
of the ’’tails’’ of histone proteins. These histone mod-
ifications alter the activity of DNA wrapped around
them. Open chromatin is transcriptionally active be-
cause it allows transcription factors to access their tar-
get genes. Condensed chromatin, on the other hand, is
transcriptionally inactive. To reverse the process of
chromatin condensation, inhibitors of histone deace-
tylases or inhibitors of DNA methyltransferases (or
both) can be employed. Such a reexpressor strategy is
now widely pursued, in hopes that improved gene ex-
pression leads to improved maturation of hematopoi-
etic cells and, thus, to more effective hematopoiesis.
A study by Silverman et al. [14] using the DNA
methyltransferase inhibitor 5-azacitidine showed that
AML transformation can be significantly delayed.
This result has recently been reproduced by a large in-
ternational confirmatory trial [15], which compared
subcutaneous azacitidine (plus best supportive care
[BSC]) with conventional care regimens, including
BSC only, low-dose AraC plus BSC, and standard in-
duction chemotherapy plus BSC. Azacitidine increased
themedian length of survival from15months to 2 years,
and doubled the 2-year survival rate from 26% to 51%.
Comparison with BSC, low-dose AraC, and standard
chemotherapy, respectively, consistently showed a dif-
ference of about 9.5 months in favor of azacitidine.
Besides increased time to AML or death, there was
improvement in terms of RBC transfusion dependence
and also a reduction of infections requiring intravenous
antibiotics. 5-Aza was well tolerated in the elderly
patient population of this trial.
The overall survival (OS) benefit was achieved with
5-Aza reatment for a median of 9 cycles. After 6 treat-
ment cycles, 87% of the responders had obtained
their first response. Therefore, epigenetic treatment
requires perseverance. It is also important to know that
patients do not have to reach CR to achieve prolonged
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a clear survival benefit. Accordingly, treatment with 5-
Aza should be continued as long as there is no evidence
of disease progression.
Decitabine (5-aza-20deoxycytidine) is structurally
very similar to 5-azacitidine. Preliminary clinical results
with decitabine were reported 2 years before the Silver-
man study [16]. The overall response rate was about
50%. Interestingly, the best results were achieved in pa-
tients with a high risk profile, in particular, patients with
high-risk karyotypes such asmonosomy 7/del(7q). Sim-
ilar to 5-azacitidine, decitabine was capable of inducing
cytogenetic remissions. Themean number of treatment
cycles necessary to reach the best observed response was
3.2. More recently, Kantarjian et al. [17] performed
a phase III randomized study of decitabine versus BSC
in MDS and showed that decitabine significantly pro-
longed the time to AML transformation, particularly
in higher risk patients. Decitabin-treated patients were
also compared with historical controls who received
intensive chemotherapy at the same institution. The
groups were matched for age, cytogenetics, and
International Prostate Symptom Score (IPSS) score.
There was a highly significant advantage for treatment
with decitabine [18].
However, a decitabine trial initiated by the
EORTC in 2002 and reported in 2008, found no sig-
nificant survival benefit. This phase III opened-label,
randomized, multicenter, controlled trial compared
BSC plus decitabin with BSC only [19]. The trial in-
cluded 233 patients over 60 years of age, predomi-
nantly with high-risk or intermediate-2 risk MDS
and marrow blasts between 11% and 30%. Although
response rates were similar to those observed in other
trials of decitabine (13% CR, 6% partial remission
[PR], 15% haematologic improvement) and progres-
sion-free survival (PFS) showed significant improve-
ment (6.6 versus 3 months), the difference in OS
(median 10.2 versus 8.5 months) was not statistically
significant. Possible causes include shorter duration
of drug exposure (6 months of decitabine, compared
to 9 months of 5-Aza in the AZA-001 trial), differences
in postprogression treatment, and a shorter interval
between diagnosis and treatment, which may have
led to inclusion of high-risk patients who would not
have been included in the AZA-001 trial because of
rapid progression. Although decitabine has been ap-
proved in the United States since 2006, approval in
Europe remains uncertain. A new EORTC trial is cur-
rently being planned, featuring a head-to-head com-
parison between decitabine and 5-azacitidine.
The mechanisms of action of decitabine and 5-
azacitidine differ. For example, decitabine is only
incorporated into DNA, whereas 90% of 5-Aza is in-
corporated into RNA. Azacytidine and decitabine (as
well as zebularine) exert differential effects on cancer
gene expression in AML cells [20]. Such pharmaco-logical differences may contribute to differences in
clinical results. Borthakur et al. [21] reported on 14
patients with MDS who had experienced azacytidine
failure or intolerance and were subsequently treated
with decitabine; 3 achieved CRs and 1 showed hema-
tological improvement, for instance, an overall re-
sponse rate of 28%. Mo¨ller et al. [22] observed
repeated responses of an elderly patient with high-
risk MDS to tipifarnib, 5-azacitidine, and decitabine.
However, most hematologists would probably agree
that neither of the demethylating agents is greatly
superior to the other.
Considering that histone deacetylation and DNA
hypermethylation cooperate in the process of gene si-
lencing, it appears attractive to combine inhibitors of
both mechanisms. For instance, experience has been
gained with valproic acid, an antiepileptic drug that
also acts as a histone deacetylase (HDAC) inhibitor.
We observed responses according to the IWG criteria
in about 50% of patients with a normal marrow blast
count, but rarely in cases with excess of blasts [23].
The average response rate over all types of MDS was
about 30%, which is in agreement with results from
other groups. We then combined valproic acid with
5-azacitidine in a poor-risk cohort of 24 patients, 7 of
whom had received previous intensive chemotherapy,
and observed an overall response rate of 33% [24]. As
a conclusion from this and other trials, one could con-
clude that combining a demethylating agent with an
HDAC inhibitor leads to faster responses in some pa-
tients. However, this approach does not seem to obviate
the need for prolonged treatment. Patients achieving at
least stable disease should be kept on treatment unless
there is evidence of disease progression [25].
The search for effective drug combinations must
continue. We are about to start a trial of valproic
acid and lenalidomide, including patients with primary
MDS who have a low or intermediate-1 risk profile
according to IPSS and\10% BM blasts.Iron Chelation Therapy
Unfortunately, many patients with MDS do not
respond, or respond only temporarily, to available treat-
ment strategies, and therefore require chronic transfu-
sion therapy, which eventually leads to iron overload.
The role of iron chelation therapy inMDS is controver-
sial, because there is a lack of controlled clinical trials.
Based on inferences from patients with thalassemia ma-
jor, cardiac problems are themost dreaded complication
of iron overload in elderlyMDSpatients.However, car-
diac iron accumulation is detectable by magnetic reso-
nance imaging only in a minority of MDS patients.
On the other hand, the presence of nontransferrin
bound iron (NTBI) and labile plasma iron (LPI)may ex-
ert toxic effects before large amounts of iron have accu-
mulated in organ parenchyma.NTBI is readily taken up
S34 Biol Blood Marrow Transplant 16:S30-S36, 2010Norbert Gattermannby the liver, heart, and endocrine glands, where it cata-
lyzes the generation of hydroxyl radicals. Experience in
thalassemia major shows that patients in heart failure
can be rescued by intensive chelation therapy before
much iron has been removed from the heart, suggesting
that substantial clinical benefit can be derived from de-
toxification of NTBI.
It has also been argued that, besides preventing
cardiac complications, iron chelation may lower infec-
tion risk, improve outcome after allogeneic HCT, and
delay leukemic transformation in patients with MDS
[26]. Transplant physicians are aware of studies corre-
lating iron overload and the presence of high LPI, on
the 1 hand, with increased transplant-associated
morbidity and mortality, particularly owing to infec-
tious complications, on the other hand. Physicians
are perhaps less well aware of the increased risk that
may arise in MDS from the unfortunate combination
of neutropenia/granulocyte dysfunction and hemosi-
derosis-related susceptibility to bacterial infections.
For many clinicians, it may also be surprising to learn
that iron overload is a risk factor for leukemic transfor-
mation, independent of transfusion requirement [27].
Why should iron overload affect the rate of leukemic
transformation? A possible explanation is that iron
overload causes oxidative stress that aggravates geno-
mic instability of the MDS clone, thereby promoting
clonal evolution toward acute leukemia. This hypoth-
esis needs to be corroborated by experimental evidence
as well as clinical trials.
Several guidelines recommend iron chelation for
transfusion-dependent MDS patients with a ‘‘reason-






















Figure 1. Risk-adapted MDS treatment algorithm usedexceeding 1000 or 1500 ng/mL. In fact, there is no uni-
versally applicable ferritin threshold that would or
should trigger iron chelation, because the intensity of
the individual patient’s transfusion regimen must be
taken into account. For many years, deferoxamine
given as subcutaneous or intravenous infusion or
subcutaneous bolus injection has been the first-line
therapy. Meanwhile, 2 oral chelators have become
available: deferiprone and deferasirox. Deferasirox
has undergone extensive clinical trials, mainly in
patients with thalassemia major, but also in other
transfusion dependent anemias, including MDS [28-
30]. A dose of at least 20 mg/kg/d is needed to achieve
a negative iron balance, as determined by a decrease in
serum ferritin levels and liver iron content.
To show that deferasirox not only reduces total-
body iron but also results in clinical benefit, a prospec-
tive, randomized, double-blinded, placebo-controlled
trial has recently been started. The goal is to determine
in low/Intermediate-1 risk MDS patients, treated as
per standard practice, the clinical superiority of defer-
asirox to placebo in terms of OS, cardiac function, and
liver function, which potentially can be affected by iron
overload complications.MDS Treatment Algorithm
At our center, we have a developed a treatment
algorithm for patients with MDS (see Figure 1):
1. For patients with low or intermediate-1 risk who
suffer from symptomatic anemia, transfusion ther-
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at the Hematology/Oncology Dept. in Du¨sseldor.
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tients with del(5q) who should receive the benefit
of lenalidomide treatment.
3. Patients with endogenous Epo levels\500 should
be treated with Epo1/2 G-CSF, those with Epo
levels .500 should be considered for immunosup-
pressive treatment (ATG) or valproic acid, or par-
ticipation in a clinical trial.
4. For patients with intermediate-2 or high-risk MDS
whoarefit and in the acceptable age range, allogeneic
HCT should be considered, with both conventional
(high dose) and reduced-intensity conditioning
(RIC) being options.
5. If no donor is available, intensive chemotherapy is
an option. However, epigenetic treatment with 5-
azacitidine is probably the treatment of choice in
the majority of patients.
6. If the karyotype is complex or includes abnormali-
ties of chromosome 7, intensive chemotherapy is
not recommended. Instead, allogeneicHCTor epi-
genetic treatment should be tried.
7. Chronic myelomonocytic leukemia (CMML) is still
included in our algorithm, even though it has been
removed from the WHO classification of MDS. If
leukocytosis requires treatment, and allogeneic
HCT is not possible, cytoreduction with hydroxy-
urea or treatment with other cytotoxic drugs is
recommended. Epigenetic treatment is another op-
tion, because demethylating agents have achieved re-
sponses in about 50% of CMML patients.ACKNOWLEDGMENTS
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